"Drug Combinations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Descriptor ID |
D004338
|
MeSH Number(s) |
D26.310
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Combinations".
Below are MeSH descriptors whose meaning is more specific than "Drug Combinations".
- Drug Combinations
- Adapalene, Benzoyl Peroxide Drug Combination
- Albuterol, Ipratropium Drug Combination
- Aminophylline
- Amlodipine Besylate, Olmesartan Medoxomil Drug Combination
- Amlodipine, Valsartan Drug Combination
- Aspirin, Dipyridamole Drug Combination
- Biphasic Insulins
- Brimonidine Tartrate, Timolol Maleate Drug Combination
- Budesonide, Formoterol Fumarate Drug Combination
- Buprenorphine, Naloxone Drug Combination
- Contraceptives, Oral, Combined
- Dimenhydrinate
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Emtricitabine, Rilpivirine, Tenofovir Drug Combination
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Ezetimibe, Simvastatin Drug Combination
- Fluticasone-Salmeterol Drug Combination
- Mometasone Furoate, Formoterol Fumarate Drug Combination
- Multi-Ingredient Cold, Flu, and Allergy Medications
- Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
- Trimethoprim, Sulfamethoxazole Drug Combination
This graph shows the total number of publications written about "Drug Combinations" by people in this website by year, and whether "Drug Combinations" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 6 | 6 |
1995 | 0 | 9 | 9 |
1996 | 0 | 5 | 5 |
1997 | 0 | 9 | 9 |
1998 | 0 | 6 | 6 |
1999 | 0 | 5 | 5 |
2000 | 0 | 12 | 12 |
2001 | 0 | 12 | 12 |
2002 | 0 | 11 | 11 |
2003 | 0 | 12 | 12 |
2004 | 0 | 19 | 19 |
2005 | 0 | 21 | 21 |
2006 | 0 | 18 | 18 |
2007 | 0 | 23 | 23 |
2008 | 0 | 16 | 16 |
2009 | 0 | 10 | 10 |
2010 | 0 | 13 | 13 |
2011 | 0 | 12 | 12 |
2012 | 0 | 9 | 9 |
2013 | 0 | 9 | 9 |
2014 | 1 | 11 | 12 |
2015 | 0 | 9 | 9 |
2016 | 0 | 14 | 14 |
2017 | 1 | 17 | 18 |
2018 | 1 | 15 | 16 |
2019 | 0 | 13 | 13 |
2020 | 0 | 22 | 22 |
2021 | 0 | 16 | 16 |
2022 | 0 | 14 | 14 |
2023 | 0 | 6 | 6 |
2024 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Combinations" by people in Profiles.
-
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. 2024 Mar 14; 15:220-231.
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
-
The mechanism of ceftazidime and cefiderocol hydrolysis by D179Y variants of KPC carbapenemases is similar and involves the formation of a long-lived covalent intermediate. Antimicrob Agents Chemother. 2024 Mar 06; 68(3):e0110823.
-
Emerging data in COVID-19 create urgent challengers for health providers: Updates on COVID-19 vaccine and Paxlovid. J Natl Med Assoc. 2024 Apr; 116(2 Pt 1):174-179.
-
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. mBio. 2024 Feb 14; 15(2):e0287423.
-
[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)]. Pneumologie. 2024 Jan; 78(1):35-46.
-
High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated ?-lactamase CMY-185 variant. J Antimicrob Chemother. 2023 10 03; 78(10):2442-2450.
-
In vitro model to simulate multiple drugs with distinct elimination half-lives. Int J Antimicrob Agents. 2023 Oct; 62(4):106924.
-
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs. J Am Heart Assoc. 2023 04 04; 12(7):e028278.
-
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Int J Chron Obstruct Pulmon Dis. 2023; 18:407-418.